奥马珠单抗联合特异性免疫治疗变应性鼻炎疗效的Meta分析

doi:10.6040/j.issn.1673-3770.0.2023.325

摘要/Abstract

摘要： 目的探讨奥马珠单抗联合特异性免疫治疗与单纯特异性免疫治疗的疗效差异,为临床治疗变应性鼻炎提供一定依据。方法采用知网、Pubmed、SinoMed、Embase和Cochrane检索文献,文献检索起止时间从建库至2023年6月,按纳入标准筛选文献并对纳入文献进行严格质量评价后提取资料,应用R 4.3.1软件进行Meta分析。结果共纳入5篇随机对照研究,共计445例患者。奥马珠单抗联合特异性免疫治疗223例,单纯特异性免疫治疗222例,Meta分析结果显示与单纯特异性免疫治疗相比,奥马珠单抗联合特异性免疫治疗严重程度评分与使用救援药物评分均降低(P<0.001),两组不良反应评分差异无统计学意义(P=0.52)。结论当前证据表明特异性免疫治疗联合奥马珠单抗较单纯特异性免疫治疗能更好控制变应性鼻炎患者临床症状,减少缓解药物的使用,但未来仍需更多大样本、多中心、双盲随机对照试验研究来进一步证实。

关键词: 变应性鼻炎, 特异性免疫治疗, 奥马珠单抗, Meta分析

Abstract: Objective To examine the disparity in effectiveness between the combination therapy of omalizumab with specific immunotherapy and specific immunotherapy alone, aiming to furnish insights for the clinical management of allergic rhinitis. Methods Computerized searches were performed using CNKI, Pubmed, SinoMed, Embase, and Cochrane, with the start and end of the literature search from the period of establishment of the database to June 2023, respectively. Data were extracted after screening the literature according to inclusion criteria and performing a rigorous quality evaluation of the included literature; meta-analysis was performed by applying R 4.3.1 software. Results Five randomized controlled studies with 445 patients were included. 223 cases of patients treated with omalizumab combined with specific immunotherapy and 222 cases of those treated with specific immunotherapy alone were analyzed. Meta-analysis showed that the severity score and use of rescue medication score were reduced in patients treated with omalizumab combined with specific immunotherapy compared to those treated with specific immunotherapy alone(P<0.001); however, differences in the scores of adverse effects between the two groups were not statistically significant(P=0.52). Conclusion Existing evidence indicates that combining omalizumab with specific immunotherapy offers superior control over clinical symptoms and reduces the need for palliative medications compared to specific immunotherapy alone in patients with allergic rhinitis. However, further confirmation through large-sample, multicentric, double-blind randomized controlled trials is warranted in the future.

Key words: Allergic rhinitis, Specific immunotherapy, Omalizumab, Meta-analysis

中图分类号:

R765

许雪萌,樊磊,喻望博,蒋芝月,潘晨,黄泳芹. 奥马珠单抗联合特异性免疫治疗变应性鼻炎疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 26-33.

XU Xuemeng, FAN Lei, YU Wangbo, JIANG Zhiyue, PAN Chen, HUANG Yongqin. Meta-analysis of the efficacy of omalizumab in combination with specific immunotherapy for allergic rhinitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 26-33.

参考文献

[1] Weaver-Agostoni J, Kosak Z, Bartlett S. Allergic rhinitis: rapid evidence review[J]. Am Fam Physician, 2023, 107(5): 466-473
[2] Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: Allergic rhinitis-2023[J]. Int Forum Allergy Rhinol, 2023, 13(4): 293-859. doi:10.1002/alr.23090
[3] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组、小儿学组, 中华儿科杂志编辑委员会. 儿童变应性鼻炎诊断和治疗指南(2010年, 重庆)[J]. 中华耳鼻咽喉头颈外科杂志, 2011, 46(1): 7-8. doi:10.3760/cma.j.issn.1673-0860.2011.01.004
[4] Tang R, Lei SB, Zhu LP, et al. Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study[J]. Front Immunol, 2022, 13: 913424. doi:10.3389/fimmu.2022.913424
[5] 李丽莎, 关凯, 王子熹, 等. 奥马珠单抗治疗柏树花粉过敏所致季节性变应性鼻炎的效果[J]. 中华临床免疫和变态反应杂志, 2022, 16(6): 569-574. doi:10.3969/j.issn.1673-8705.2022.06.001 LI Lisha, GUAN Kai, WANG Zixi, et al. Efficacy of omalizumab in treatment of Sabina chinensis pollen-induced seasonal allergic rhinitis[J]. Chinese Journal of Allergy and Clinical Immunology, 2022, 16(6): 569-574. doi:10.3969/j.issn.1673-8705.2022.06.001
[6] Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials[J]. BMJ, 2011, 343: d5928. doi:10.1136/bmj.d5928
[7] 王丹, 翟俊霞, 牟振云, 等. Meta分析中的异质性及其处理方法[J]. 中国循证医学杂志, 2009, 9(10): 1115-1118
[8] Bozek A, Kozowska R, Misioek M, et al. Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis[J]. Hum Vaccin Immunother, 2022, 18(6): 2097818. doi:10.1080/21645515.2022.2097818
[9] Kamin W, Kopp MV, Erdnuess F, et al. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously[J]. Pediatr Allergy Immunol, 2010, 21(1 pt 2): e160-e165. doi:10.1111/j.1399-3038.2009.00900.x
[10] Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma[J]. Clin Exp Allergy, 2009, 39(2): 271-279. doi:10.1111/j.1365-2222.2008.03121.x
[11] Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis[J]. J Allergy Clin Immunol, 2006, 117(1): 134-140. doi:10.1016/j.jaci.2005.09.036
[12] Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children[J]. Allergy, 2004, 59(9): 973-979. doi:10.1111/j.1398-9995.2004.00552.x
[13] Xu QY, Tian M, Lu M, et al. The role of allergen-specific immunotherapy in the primary and secondary prevention of allergic diseases[J]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2023, 58(12): 1259-1265. doi:10.3760/cma.j.cn115330-20230506-00209
[14] 符文婷. 变应性鼻炎皮下特异性免疫治疗的疗效及安全性研究[D]. 扬州: 扬州大学, 2023
[15] Pfaar O, Gehrt F, Li HS, et al. Anti-IgE: a treatment option in allergic rhinitis [J]. Allergol Select, 2021, 5: 119-127. doi:10.5414/ALX02205E
[16] 王剑, 杜伟嘉, 薛涛, 等. 利用百度指数分析中国过敏性鼻炎及相关变应性疾病的流行特征[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 31-41. doi:10.6040/j.issn.1673-3770.0.2022.401 WANG Jian, DU Weijia, XUE Tao, et al. Analysis of the epidemic characteristics of allergic rhinitis and related allergic diseases in China using Baidu index data[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 31-41. doi:10.6040/j.issn.1673-3770.0.2022.401
[17] 倪璟滋, 万文锦. 变应性鼻炎健康相关生活质量研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 110-115, 122. doi:10.6040/j.issn.1673-3770.1.2021.165 NI Jingzi, WAN Wenjin. Research progress on health-related quality of life in allergic rhinitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 110-115, 122. doi:10.6040/j.issn.1673-3770.1.2021.165
[18] 胡晶, 戴娜, 蔺婷, 等. 变应性鼻炎的临床治疗[J]. 中国中西医结合耳鼻咽喉科杂志, 2017, 25(3): 237-240. doi:10.16542/j.cnki.issn.1007-4856.2017.03.020 HU Jing, DAI Na, LIN Ting, et al. Clinical treatment of allergic rhinitis[J]. Chinese Journal of Otorhinolaryngology in Integrative Medicine, 2017, 25(3): 237-240. doi:10.16542/j.cnki.issn.1007-4856.2017.03.020
[19] 江银丽, 朱新华. 免疫治疗在变应性鼻炎免疫调节机制中的作用研究[J]. 临床耳鼻咽喉头颈外科杂志, 2018, 32(18): 1440-1443. doi:10.13201/j.issn.1001-1781.2018.18.020 JIANG Yinli, ZHU Xinhua. Research on immune regulation mechanism of immunotherapy for allergic rhinitis[J]. Journal of Clinical Otorhinolaryngology Head and Neck Surgery, 2018, 32(18): 1440-1443. doi:10.13201/j.issn.1001-1781.2018.18.020
[20] 卢蓉蓉, 张兰, 郑洁, 等. 变应原特异性免疫治疗在变应性鼻炎伴哮喘治疗中的临床疗效[J]. 医学研究杂志, 2023, 52(4): 138-147. doi:10.11969/j.issn.1673-548X.2023.04.031 LU Rongrong, ZHANG Lan, ZHENG Jie, et al. Clinical efficacy of allergen specific immunotherapy in the treatment of allergic rhinitis with asthma[J]. Journal of Medical Research, 2023, 52(4): 138-147. doi:10.11969/j.issn.1673-548X.2023.04.031
[21] Altas U, Cetemen A, Altas ZM, et al. Retrospective evaluation of adverse reactions after subcutaneous allergen-specific immunotherapy in children with house dust mite allergy[J]. North Clin Istanb, 2023, 10(5): 675-680. doi:10.14744/nci.2023.78871
[22] 江育蔺, 王心悦, 唐隽, 等. 珠三角地区变应性鼻炎和/或支气管哮喘患者皮下特异性免疫治疗依从性的真实世界研究[J]. 中山大学学报(医学科学版), 2022, 43(1): 18-26. doi:10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0 JIANG Yulin, WANG Xinyue, TANG Jun, et al. Real world study on compliance of subcutaneous specific immunotherapy in patients with allergic rhinitis and/or bronchial asthma in the Pearl River Delta region[J]. Journal of Sun Yat-sen University(Medical Sciences), 2022, 43(1): 18-26. doi:10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0
[23] Okayama Y, Matsumoto H, Odajima H, et al. Roles of omalizumab in various allergic diseases[J]. Allergol Int, 2020, 69(2): 167-177. doi:10.1016/j.alit.2020.01.004
[24] Yan HC, Sun L, Ni YM, et al. Effective omalizumab treatment influenced eosinophil function in severe allergic asthmatics[J]. J Thorac Dis, 2023, 15(6): 3115-3125. doi:10.21037/jtd-22-1818
[25] Tsabouri S, Ntritsos G, Koskeridis F, et al. Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis[J]. Rhinology, 2021, 59(6): 501-510. doi:10.4193/Rhin21.159
[26] Zhang Y, Xi L, Gao YB, et al. Omalizumab is effective in the preseasonal treatment of seasonal allergic rhinitis[J]. Clin Transl Allergy, 2022, 12(1): e12094. doi:10.1002/clt2.12094
[27] Yu CJ, Wang KJ, Cui XY, et al. Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials[J]. Am J Rhinol Allergy, 2020, 34(2): 196-208. doi:10.1177/1945892419884774
[28] 叶菁, 徐睿, 邱前辉, 等. 抗IgE单抗治疗变应性鼻炎专家共识(南昌, 2022)[J]. 中华临床免疫和变态反应杂志, 2022, 16(5): 458-468. doi:10.3969/j.issn.1673-8705.2022.05.002 YE Jing, XU Rui, QIU Qianhui, et al. Expert consensus on use of anti-IgE monoclonal antibody in management of allergic rhi- nitis(Nanchang, 2022)[J]. Chinese Journal of Allergy and Clinical Immunology, 2022, 16(5): 458-468. doi:10.3969/j.issn.1673-8705.2022.05.002
[29] 高培, 余文婷, 周玥, 等. 奥马珠单抗联合RIT与糖皮质激素联合RIT的安全性比较[J]. 临床耳鼻咽喉头颈外科杂志, 2020, 34(7): 610-614. doi:10.13201/j.issn.2096-7993.2020.07.008 GAO Pei, YU Wenting, ZHOU Yue, et al. Safety comparison of omalizumab and glucocorticoid in rush allergen immunotherapy[J]. Journal of Clinical Otorhinolaryngology Head and Neck Surgery, 2020, 34(7): 610-614. doi:10.13201/j.issn.2096-7993.2020.07.008
[30] De Filippo M, Votto M, Caminiti L, et al. Omalizumab and allergen immunotherapy for respiratory allergies: a mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology(SIAIP)[J]. Allergol Immunopathol, 2022, 50(6): 47-52. doi:10.15586/aei.v50i6.495
[31] MacGlashan DW Jr, Savage JH, Wood RA, et al. Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors[J]. J Allergy Clin Immunol, 2012, 130(5): 1130-1135.e5. doi:10.1016/j.jaci.2012.05.038
[32] Macglashan DW Jr, Saini SS. Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation[J]. J Allergy Clin Immunol, 2013, 132(4): 906-911.e1-4. doi:10.1016/j.jaci.2013.04.056
[33] Bo ek A, Fischer A, Bogacz-Piaseczynska A, et al. Adding a biologic to allergen immunotherapy increases treatment efficacy[J]. ERJ Open Res, 2023, 9(2): 00639-02022. doi:10.1183/23120541.00639-2022
[34] Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma[J]. J Allergy Clin Immunol, 2010, 125(2): 383-389. doi:10.1016/j.jaci.2009.11.022

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed